What Is Hepatocellular Carcinoma?

Hepatocellular carcinoma is a primary liver cancer that starts in hepatocytes, the main cells responsible for performing most liver functions. These cells help process nutrients, make proteins, produce bile, store energy, and remove substances the body does not need. In other words, the liver is part factory, part warehouse, and part cleanup crewwith no vacation policy.

HCC is different from metastatic liver cancer. A tumor that starts in the colon, breast, lung, or another organ and later spreads to the liver is named and treated according to its original location. HCC begins inside the liver itself.

Most cases develop in people with long-term liver damage, particularly cirrhosis. However, HCC can occasionally occur without cirrhosis, especially in people with chronic hepatitis B infection.

Hepatocellular Carcinoma Symptoms

Early HCC may produce no obvious symptoms. When symptoms do develop, they can resemble those of cirrhosis, hepatitis, gallbladder disease, or other digestive conditions. A new symptom does not automatically mean cancer, but persistent or worsening changes deserve medical attention.

Common HCC symptoms include:

• Unexplained weight loss
• Reduced appetite
• Feeling full after eating a small amount
• Persistent nausea or vomiting
• Pain or discomfort in the upper-right abdomen
• A firm lump or feeling of fullness below the right ribs
• Swelling caused by fluid buildup in the abdomen
• Yellow skin or eyes, known as jaundice
• Dark urine or unusually pale stools
• Persistent itching
• Fatigue, weakness, or reduced stamina
• Easy bruising or bleeding
• Fever without an obvious infection
• Pain near the right shoulder blade or upper back

People who already have cirrhosis should also report a sudden worsening of abdominal swelling, confusion, jaundice, appetite, or energy. These changes may indicate liver decompensation, HCC, an infection, internal bleeding, or another complication requiring prompt evaluation.

When symptoms require urgent care

Seek urgent medical help for vomiting blood, black or tarry stools, severe abdominal pain, rapidly increasing abdominal swelling, fainting, breathing difficulty, high fever, or new confusion. These symptoms can signal internal bleeding, infection, liver failure, or another emergency.

What Causes HCC?

HCC develops when genetic changes cause liver cells to grow and divide abnormally. Doctors usually cannot identify one precise event that transformed a particular cell. Instead, years of inflammation, injury, cell repair, and scarring can create an environment in which cancer is more likely to develop.

Chronic hepatitis B

Long-term hepatitis B virus infection is a major HCC risk factor worldwide. Hepatitis B can increase liver cancer risk even before cirrhosis develops. Antiviral treatment can reduce complications, but people at continued risk may still need regular cancer surveillance.

Chronic hepatitis C

Untreated hepatitis C can gradually cause fibrosis and cirrhosis. Modern antiviral medications cure most hepatitis C infections, substantially reducing future liver complications. However, someone who already has cirrhosis may remain at increased HCC risk even after the virus is cured.

Cirrhosis

Cirrhosis is extensive scarring that distorts the liver’s normal structure. It may result from viral hepatitis, long-term heavy alcohol use, metabolic liver disease, autoimmune conditions, or inherited disorders. Most HCC cases in the United States occur in people with underlying chronic liver disease.

MASLD and MASH

Metabolic dysfunction-associated steatotic liver disease, or MASLD, involves excess fat in the liver in combination with metabolic risk factors. Its inflammatory form, MASH, can lead to progressive scarring, cirrhosis, and HCC. Risk is especially concerning when fatty liver disease occurs alongside obesity, insulin resistance, or type 2 diabetes.

Additional risk factors

• Long-term heavy alcohol consumption
• Smoking
• Type 2 diabetes
• Obesity and metabolic syndrome
• Hemochromatosis, which causes excessive iron storage
• Certain inherited metabolic or liver disorders
• Older age and male sex
• A family history of liver cancer
• Exposure to aflatoxins from contaminated food, more commonly in regions without strict food-storage controls

Having a risk factor does not guarantee that HCC will develop, and some people have several risk factors without ever getting cancer. Risk factors help clinicians identify who may benefit from closer monitoring.

HCC Screening and Surveillance

Routine liver cancer screening is not recommended for every adult. Surveillance is generally reserved for people whose risk is high enough to justify repeated testing, including many people with cirrhosis and selected groups with chronic hepatitis B.

A common surveillance approach is a liver ultrasound with a blood test for alpha-fetoprotein, or AFP, approximately every six months. The exact plan may differ according to the cause of liver disease, age, family history, ethnicity, liver function, transplant eligibility, and the quality of ultrasound images.

Surveillance is not the same as diagnosis. Its purpose is to discover a suspicious change while it may still be small and treatable. Missing repeated appointments can allow an early, quiet tumor to become a considerably noisier problem later.

How Hepatocellular Carcinoma Is Diagnosed

Medical history and examination

A clinician will review liver disease history, alcohol use, medications, viral hepatitis testing, weight changes, symptoms, and family history. The examination may look for jaundice, abdominal fluid, an enlarged liver, muscle loss, bruising, or signs of advanced liver disease.

Blood tests

Testing may include liver enzymes, bilirubin, albumin, blood counts, kidney function, clotting measurements, hepatitis tests, and AFP. AFP can support the evaluation, but it is not a perfect cancer detector. Some HCC tumors do not raise AFP, while hepatitis, pregnancy, and other conditions may increase it. AFP alone should not confirm or exclude HCC.

Ultrasound, CT, and MRI

A suspicious ultrasound finding is usually evaluated with a multiphase contrast-enhanced CT scan or MRI. HCC often has a recognizable blood-flow pattern: it enhances during the arterial phase and becomes less enhanced than the surrounding liver during later phases.

In a person with cirrhosis or another high-risk condition, characteristic imaging findings may establish the diagnosis without a biopsy. A biopsy may be recommended when imaging is inconclusive, the patient does not have a typical high-risk background, or the result would change treatment decisions.

Staging the cancer and the liver

HCC staging is more complicated than measuring a tumor and assigning it a number. Clinicians must consider the number and size of tumors, invasion into blood vessels, spread outside the liver, liver function, portal hypertension, and the person’s ability to manage daily activities.

The Barcelona Clinic Liver Cancer system is commonly used because it combines tumor stage, liver function, and general health. A person with a small tumor but severe liver failure may need a different strategy from someone with a larger tumor and otherwise healthy liver tissue.

Hepatocellular Carcinoma Treatment

HCC treatment is best planned by a multidisciplinary team that may include a hepatologist, medical oncologist, liver surgeon, transplant specialist, interventional radiologist, radiation oncologist, pathologist, and palliative care clinician. Treatment decisions are rarely based on tumor size alone.

Surgical resection

A partial hepatectomy removes the tumor along with a margin of surrounding tissue. It may provide long-term cancer control when HCC is confined to one area and enough healthy, functional liver will remain. Significant portal hypertension or poor liver reserve can make resection unsafe even when the tumor looks technically removable.

Liver transplantation

A transplant replaces the entire diseased liver with a donor organ, treating both the cancer and the underlying cirrhosis. It is generally considered for carefully selected patients whose tumors remain within accepted size and number limits and have not spread outside the liver.

Because donor organs are limited, some patients receive ablation, embolization, or radiation to control the tumor while waiting. Transplant recipients also require lifelong medication to prevent organ rejection.

Ablation

Ablation destroys a tumor without removing it. Radiofrequency and microwave ablation use heat, while cryoablation uses extreme cold. Ablation may be particularly effective for small tumors when surgery is not appropriate. Location matters because tumors near major bile ducts, blood vessels, or other organs can be more difficult to treat safely.

Embolization and radioembolization

HCC tumors often receive much of their blood supply from the hepatic artery. Embolization treatments use this feature to target the tumor through a catheter placed in an artery.

• Transarterial chemoembolization: TACE delivers cancer medication and blocks blood flow to the tumor.
• Transarterial embolization: TAE blocks the tumor’s arterial blood supply without chemotherapy.
• Radioembolization: Also called selective internal radiation therapy, this treatment delivers tiny radioactive particles into vessels feeding the tumor.

Radiation therapy

Stereotactic body radiation therapy can deliver precisely focused radiation to selected liver tumors. Radiation may be considered when surgery or ablation is unsuitable, as a bridge to transplantation, or as part of treatment for recurrent or more advanced disease.

Immunotherapy and targeted therapy

Systemic therapy travels through the bloodstream and is generally used for unresectable, metastatic, or otherwise advanced HCC. Immunotherapy helps the immune system recognize and attack cancer. Targeted drugs interfere with signals involved in tumor growth or blood-vessel formation.

Depending on previous treatment, liver function, bleeding risk, autoimmune conditions, and other health factors, options may include immunotherapy combinations, an immunotherapy paired with an anti-angiogenic drug, or a targeted tyrosine kinase inhibitor. FDA-approved examples include atezolizumab with bevacizumab, durvalumab with tremelimumab, nivolumab with ipilimumab, sorafenib, and lenvatinib. The nivolumab-ipilimumab combination received FDA approval in April 2025 as a first-line option for adults with unresectable or metastatic HCC.

These treatments can cause significant side effects. Immunotherapy may trigger inflammation in healthy organs, while targeted treatments may cause high blood pressure, diarrhea, fatigue, skin reactions, or appetite changes. New symptoms should be reported rather than quietly tolerated as an unwanted membership fee for receiving treatment.

Palliative and supportive care

Palliative care is not limited to the final stage of an illness. It can be added at any point to manage pain, nausea, fatigue, itching, appetite problems, sleep disruption, anxiety, and family stress. It works alongside cancer treatment rather than replacing it.

Can HCC Come Back After Treatment?

HCC can recur after resection, ablation, or other apparently successful treatment. A recurrence may represent remaining cancer cells or a new tumor developing in liver tissue that is still chronically damaged.

Follow-up commonly includes imaging, blood tests, AFP measurements when useful, and ongoing management of hepatitis, cirrhosis, diabetes, alcohol use, or metabolic liver disease. The schedule is usually more frequent immediately after treatment and may be adjusted according to the original tumor and recurrence risk.

HCC Prognosis and Outlook

Prognosis depends on the stage at diagnosis, number of tumors, blood-vessel involvement, spread outside the liver, remaining liver function, overall health, and response to treatment. Early HCC that can be removed, transplanted, or completely ablated has a substantially better outlook than cancer discovered after vascular invasion or distant spread.

Statistics describe groups, not individual outcomes. They may also lag behind current medical practice because newer combinations and liver-directed treatments are continually changing care. A treating specialist can provide a more meaningful estimate based on the person’s imaging, liver scores, laboratory results, and treatment response.

How to Reduce the Risk of Hepatocellular Carcinoma

Not every case can be prevented, but many major HCC risk factors are manageable.

• Receive hepatitis B vaccination when recommended.
• Get tested for hepatitis B and hepatitis C based on current screening guidance and personal risk.
• Complete antiviral treatment when prescribed.
• Avoid sharing needles, razors, or equipment exposed to blood.
• Limit or avoid alcohol, particularly with existing liver disease.
• Do not smoke.
• Work toward a sustainable weight and regular physical activity.
• Manage diabetes, cholesterol, and blood pressure.
• Attend recommended liver cancer surveillance appointments.
• Discuss herbs and dietary supplements with a clinician because “natural” products can still injure the liver.

There is no juice cleanse, detox powder, or heroic amount of kale that can substitute for hepatitis treatment, cirrhosis care, or scheduled imaging. Prevention is usually less glamorous: vaccinations, laboratory tests, medication adherence, sensible nutrition, and appointments kept on time.

Experiences People May Have During HCC Diagnosis and Treatment

The following discussion reflects common, representative experiences reported during liver cancer care. It is not a personal testimonial, and every patient’s experience is different.

The diagnosis may arrive during an ordinary checkup

Some people learn they have HCC after seeking care for pain, jaundice, weight loss, or abdominal swelling. Others feel completely normal when a routine surveillance ultrasound discovers a small nodule. This second experience can be especially disorienting: someone may walk into an appointment expecting a predictable cirrhosis check and walk out with orders for a contrast MRI.

The waiting period between an abnormal ultrasound and definitive imaging is often emotionally difficult. Patients sometimes call it “scanxiety”a lighthearted word for a very real form of stress. Writing down questions, bringing a trusted person to appointments, and asking when results should be available can make the uncertainty more manageable.

Appointments can feel like an alphabet parade

HCC care introduces patients to AFP, CT, MRI, TACE, TARE, SBRT, MELD, BCLC, and other abbreviations at impressive speed. It is reasonable to ask clinicians to stop, translate, and explain why a particular test or treatment is being recommended. Patients may also benefit from keeping one notebook or digital document containing medication lists, laboratory results, scan dates, symptoms, and questions.

Because both cancer and liver disease affect treatment decisions, recommendations may initially seem contradictory. One clinician may focus on destroying the tumor, while another is concerned about preserving enough liver function. This is exactly why multidisciplinary review matters.

Treatment days vary widely

A person undergoing ablation may have a relatively short hospital stay but experience temporary soreness and fatigue. After TACE or radioembolization, some patients report pain, nausea, fever, or profound tiredness for several days. Systemic treatment may involve regular infusions, injections, pills, blood tests, blood-pressure checks, and repeated scans.

Side effects should not be saved for the next appointment like receipts in a kitchen drawer. Fever, worsening jaundice, bleeding, severe diarrhea, breathing problems, confusion, or rapidly increasing abdominal swelling may require immediate medical advice. Early reporting also allows the treatment team to adjust medications before side effects become harder to control.

Food and energy can become daily projects

Appetite loss, nausea, early fullness, fluid buildup, and altered taste may make full meals difficult. Many patients find smaller, more frequent meals easier. A liver or oncology dietitian can help balance calories, protein, sodium restrictions, diabetes management, and food preferences without turning every plate into a chemistry exam.

Fatigue may continue even on days without treatment. Planning essential activities for higher-energy periods and accepting help with transportation, meals, childcare, or household work can preserve energy for recovery.

The emotional workload deserves treatment too

HCC can create fear about recurrence, transplantation, finances, work, caregiving, and the future. Some patients feel pressure to remain relentlessly positive, which can become exhausting. Honest emotions do not indicate failure. Oncology social workers, counselors, support groups, spiritual-care providers, and palliative care teams can provide practical and emotional support.

Caregivers also need information and rest. A shared calendar, written emergency plan, updated medication list, and clear division of responsibilities can reduce confusion. The most useful help is often specific: driving to an MRI, preparing a low-sodium meal, taking notes at an appointment, or simply sitting nearby without trying to turn every conversation into a motivational speech.

Questions to Ask the Treatment Team

• How certain is the diagnosis, and is a biopsy needed?
• What stage is the HCC, and how well is my liver functioning?
• Is the goal to cure the cancer, control it, or relieve symptoms?
• Could I be evaluated for surgical removal or liver transplantation?
• Would ablation, embolization, radioembolization, or radiation be appropriate?
• Which systemic treatments are reasonable, and why?
• What side effects require an immediate call?
• Should my case be reviewed by a multidisciplinary liver tumor board?
• Are clinical trials available?
• How often will I need imaging after treatment?

Conclusion

Hepatocellular carcinoma is a complex cancer because doctors must treat the tumor while protecting a liver that may already be scarred or weakened. Symptoms can include upper-right abdominal pain, weight loss, early fullness, swelling, fatigue, and jaundice, although early tumors often cause no warning signs.

Regular surveillance can help high-risk patients find HCC at a more treatable stage. Treatment may involve resection, liver transplantation, ablation, embolization, radiation, immunotherapy, targeted therapy, or several approaches used in sequence. The best decisions come from individualized assessment and coordination among liver and cancer specialists.